<DOC>
	<DOCNO>NCT01539291</DOCNO>
	<brief_summary>This study ( GS-US-312-0117 ) multicenter , 2-arm , double-blind , parallel-group extension study companion study Study GS-US-312-0116 , evaluate effect idelalisib onset , magnitude , duration tumor control .</brief_summary>
	<brief_title>Extension Study Idelalisib Patients With Chronic Lymphocytic Leukemia Who Participated GS-US-312-0116</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Inclusion : Subjects primary Phase 3 study ( Study GSUS3120116 ) compliant Tolerating primary study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>CAL-101</keyword>
	<keyword>CAL 101</keyword>
	<keyword>GS-1101</keyword>
	<keyword>GS 1101</keyword>
	<keyword>PI3K</keyword>
	<keyword>Leukemia</keyword>
	<keyword>GS-US-312-0116</keyword>
	<keyword>idelalisib</keyword>
</DOC>